THE EFFECTS OF EXENATIDE TREATMENT ON METABOLIC PARAMETERS, GHRELIN, GDF-15 AND FGF-21 IN OBESE TYPE 2 DIABETIC PATIENTS

Basit Öğe Kaydı
dc.contributor.authorYılmaz, Müge Özsan
dc.contributor.authorÖzcan, Oğuzhan
dc.date.accessioned2024-09-19T16:22:24Z
dc.date.available2024-09-19T16:22:24Z
dc.date.issued2022
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractObjective: Exenatide and similar drugs which have Glucagon Like Peptide-1(GLP-1) like effects have been used frequently in the treatment of diabetes and obesity in recent years. In this study we aimed to investigate the effects of exenatide on ghrelin, FGF-21 and GDF-15 which are known to be associated with appetite and metabolic disorders.Material and Methods: Thirty patients with Type 2 Diabetes Mellitus with a Body Mass Index of 35 kg/m2 and above who are still ongoing treatment for diabetes but not on target (HbA1c>7%) and exenatide treatment was started were included in the study. Venous blood samples were collected for the measurements of complete blood count, biochemical parameters, HbA1c, ghrelin, FGF-21, GDF-15. After 3 months of treatment initial evaluations and biochemical tests were repeated.Results: Mean age of the patients was 50.43±10.35 years. Twenty-one (70%) were female and 9 (30%) were male. Mean Hb A1c of the patients was 9.68±2.02%. After 3 months of exenatide treatment a significant decrease in body weight and body mass index was observed (p<0.001). There was also significant decrease in Ghrelin and GDF-15 levels (p<0.001).Conclusion: Our study is the first study in which these three markers were evaluated together in obese type 2 diabetics. It is thought to be that Ghrelin, FGF-21 and GDF-15 are play role in obesity and type 2 diabetes mellitus pathogenesis together in different ways.en_US
dc.identifier.doi10.24938/kutfd.1014625
dc.identifier.endpage117en_US
dc.identifier.issn2148-9645
dc.identifier.issue1en_US
dc.identifier.startpage110en_US
dc.identifier.trdizinid1120256en_US
dc.identifier.urihttps://doi.org/10.24938/kutfd.1014625
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1120256
dc.identifier.urihttps://hdl.handle.net/20.500.12483/15827
dc.identifier.volume24en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofKırıkkale Üniversitesi Tıp Fakültesi Dergisien_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectObesityen_US
dc.subjectexenatideen_US
dc.subjectghrelinen_US
dc.subjectFibroblast Growth Factor 21en_US
dc.subjectGrowth Differentiation Factor 15en_US
dc.titleTHE EFFECTS OF EXENATIDE TREATMENT ON METABOLIC PARAMETERS, GHRELIN, GDF-15 AND FGF-21 IN OBESE TYPE 2 DIABETIC PATIENTSen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
15827.pdf
Boyut:
391.76 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu